Advertisement

Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

Published:October 02, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.09.016
      Statin pretreatment has been reported to have a cardioprotective effect in patients undergoing elective or urgent percutaneous coronary intervention (PCI). However, data on patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI are still controversial. We prospectively evaluated the effect of long-term statin therapy on infarct size (IS), myocardial salvage index (MSI), and microvascular obstruction (MVO) in consecutive patients with STEMI who underwent primary PCI. Two-hundred thirty patients with STEMI (mean age 61 ± 11 years, 183 men) who underwent primary PCI were evaluated with cardiac magnetic resonance (CMR) imaging during hospitalization (median 4 days after primary PCI). In all patients, we measured peak troponin I level, whereas IS, MSI, and MVO were determined by CMR. Fifty patients (22%) were on long-term statin therapy and showed a significantly lower troponin I peak value compared to patients without previous statins (54 ± 47 vs 88 ± 106 ng/ml; p = 0.02). At CMR evaluation, IS related to the index event was significantly smaller (12.5 ± 11.5 vs 18.5 ± 18.5 g, p = 0.05), and MSI was higher (0.68 ± 0.25 vs 0.52 ± 0.30; p <0.01) in patients with previous statin therapy. MVO was also less frequent (10% vs 20%; p = 0.14) in this group. At multivariate analysis, previous statin therapy remained significantly associated with IS and MSI (p = 0.05 and 0.02, respectively). In conclusion, this study suggests that long-term statin therapy before primary PCI in patients with STEMI is associated with smaller IS and higher MSI. Future studies are warranted to confirm these findings and to investigate potential clinical implications.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Keeley E.C.
        • Boura J.A.
        • Grines C.L.
        Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.
        Lancet. 2003; 361: 13-20
        • Keeley E.C.
        • Hillis L.D.
        Primary PCI for myocardial infarction with ST-segment elevation.
        N Engl J Med. 2007; 356: 47-54
        • Ndrepepa G.
        • Tiroch K.
        • Fusaro M.
        • Keta D.
        • Seyfarth M.
        • Byrne R.A.
        • Pache J.
        • Alger P.
        • Mehilli J.
        • Schömig A.
        • Kastrati A.
        5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction.
        J Am Coll Cardiol. 2010; 55: 2383-2389
        • Niccoli G.
        • Burzotta F.
        • Galiuto L.
        • Crea F.
        Myocardial no-reflow in humans.
        J Am Coll Cardiol. 2009; 54: 281-292
        • Crea F.
        Coronary microvascular obstruction—a puzzle with many pieces.
        N Engl J Med. 2015; 372: 1464-1465
        • Bauer T.
        • Bohm M.
        • Zahn R.
        • Junger C.
        • Koeth O.
        • Gitt A.
        • Bestehorn K.
        • Senges J.
        • Zeymer U.
        Effect of chronic statin pretreatment on hospital outcome in patients with acute non-ST-elevation myocardial infarction.
        J Cardiovasc Pharmacol. 2009; 53: 132-136
        • Patti G.
        • Pasceri V.
        • Colonna G.
        • Miglionico M.
        • Fischetti D.
        • Sardella G.
        • Montinaro A.
        • Di Sciascio G.
        Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
        J Am Coll Cardiol. 2007; 49: 1272-1278
        • Pasceri V.
        • Patti G.
        • Nusca A.
        • Pristipino C.
        • Richichi G.
        • Di Sciascio G.
        • ARMYDA Investigators
        Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
        Circulation. 2004; 110: 674-678
        • Yun K.H.
        • Jeong M.H.
        • Oh S.K.
        • Rhee S.J.
        • Park E.M.
        • Lee E.M.
        • Yoo N.J.
        • Kim N.H.
        • Ahn Y.K.
        • Jeong J.W.
        The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
        Int J Cardiol. 2009; 137: 246-251
        • Li X.D.
        • Yang Y.J.
        • Geng Y.J.
        • Cheng Y.T.
        • Zhang H.T.
        • Zhao J.L.
        • Yuan J.Q.
        • Gao R.L.
        The cardioprotection of simvastatin in reperfused swine hearts relates to the inhibition of myocardial edema by modulating aquaporins via the PKA pathway.
        Int J Cardiol. 2013; 167: 2657-2666
        • Weinberg E.O.
        • Scherrer-Crosbie M.
        • Picard M.H.
        • Nasseri B.A.
        • MacGillivray C.
        • Gannon J.
        • Lian Q.
        • Bloch K.D.
        • Lee R.T.
        Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
        Am J Physiol Heart Circ Physiol. 2005; 288: H1802-H1809
        • Fuernau G.
        • Eitel I.
        • Wöhrle J.
        • Kerber S.
        • Lauer B.
        • Pauschinger M.
        • Schwab J.
        • Birkemeyer R.
        • Pfeiffer S.
        • Mende M.
        • Brosteanu O.
        • Neuhaus P.
        • Desch S.
        • de Waha S.
        • Gutberlet M.
        • Schuler G.
        • Thiele H.
        Impact of long-term statin pretreatment on myocardial damage in ST elevation myocardial infarction (from the AIDA STEMI CMR Substudy).
        Am J Cardiol. 2014; 114: 503-509
        • Kim J.S.
        • Kim J.
        • Choi D.
        • Lee C.J.
        • Lee S.H.
        • Ko Y.G.
        • Hong M.K.
        • Kim B.K.
        • Oh S.J.
        • Jeon D.W.
        • Yang J.Y.
        • Cho J.R.
        • Lee N.H.
        • Cho Y.H.
        • Cho D.K.
        • Jang Y.
        Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
        JACC Cardiovasc Interv. 2010; 3: 332-339
        • Post S.
        • Post M.C.
        • van den Branden B.J.
        • Eefting F.D.
        • Goumans M.J.
        • Stella P.R.
        • van Es H.W.
        • Wildbergh T.X.
        • Rensing B.J.
        • Doevendans P.A.
        Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial.
        Catheter Cardiovasc Interv. 2012; 80: 756-765
        • Hahn J.Y.
        • Kim H.J.
        • Choi Y.J.
        • Jo S.H.
        • Kim H.J.
        • Lee S.
        • Ahn K.J.
        • Song Y.B.
        • Choi J.H.
        • Choi S.H.
        • Choi Y.J.
        • Lee K.H.
        • Lee S.H.
        • Gwon H.C.
        Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
        Am Heart J. 2011; 162: 1026-1033
        • Ko Y.G.
        • Won H.
        • Shin D.H.
        • Kim J.S.
        • Kim B.K.
        • Choi D.
        • Hong M.K.
        • Bae J.H.
        • Lee S.
        • Lim D.S.
        • Jang Y.
        Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY Study).
        Am J Cardiol. 2014; 114: 29-35
        • Kim J.W.
        • Yun K.H.
        • Kim E.K.
        • Kim Y.C.
        • Joe D.Y.
        • Ko J.S.
        • Rhee S.J.
        • Lee E.M.
        • Yoo N.J.
        • Kim N.H.
        • Oh S.K.
        • Jeong J.W.
        Effect of high dose rosuvastatin loading before primary percutaneous coronary intervention on infarct size in patients with ST-segment elevation myocardial infarction.
        Korean Circ J. 2014; 44: 76-81
        • TIMI Study Group
        The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. TIMI study group.
        N Engl J Med. 1985; 312: 932-936
        • Schulz-Menger J.
        • Bluemke D.A.
        • Bremerich J.
        • Flamm S.D.
        • Fogel M.A.
        • Friedrich M.G.
        • Kim R.J.
        • von Knobelsdorff-Brenkenhoff F.
        • Kramer C.M.
        • Pennell D.J.
        • Plein S.
        • Nagel E.
        Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing.
        J Cardiovasc Magn Reson. 2013; 15: 35
        • Bondarenko O.
        • Beek A.M.
        • Hofman M.B.
        • Kühl H.P.
        • Twisk J.W.
        • van Dockum W.G.
        • Visser C.A.
        • van Rossum A.C.
        Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast enhanced CMR.
        J Cardiovasc Magn Reson. 2005; 7: 481-485
        • Gazzerro P.
        • Proto M.C.
        • Gangemi G.
        • Malfitano A.M.
        • Ciaglia E.
        • Pisanti S.
        • Santoro A.
        • Laezza C.
        • Bifulco M.
        Pharmacological actions of statins: a critical appraisal in the management of cancer.
        Pharmacol Rev. 2012; 64: 102-146
        • Heestermans A.A.
        • van Werkum J.W.
        • Taubert D.
        • Seesing T.H.
        • von Beckerath N.
        • Hackeng C.M.
        • Schömig E.
        • Verheugt F.W.
        • ten Berg J.M.
        Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction.
        Thromb Res. 2008; 122: 776-781
        • Wassmann S.
        • Faul A.
        • Hennen B.
        • Scheller B.
        • Bohm M.
        • Nickenig G.
        Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
        Circ Res. 2003; 93: 98-103
        • Hinoi T.
        • Matsuo S.
        • Tadehara F.
        • Tsujiyama S.
        • Yamakido M.
        Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography.
        Am J Cardiol. 2005; 96: 89-91
        • Ray K.K.
        • Cannon C.P.
        Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?.
        Am J Cardiol. 2005; 96: 54-60
        • Matetzky S.
        • Fefer P.
        • Shenkman B.
        • Shechter M.
        • Novikov I.
        • Savion N.
        • Varon D.
        • Hod H.
        Statins have an early antiplatelet effect in patients with acute myocardial infarction.
        Platelets. 2011; 22: 103-110
        • Celik T.
        • Kursaklioglu H.
        • Iyisoy A.
        • Kose S.
        • Kilic S.
        • Amasyali B.
        • Kardesoglu E.
        • Isik E.
        The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction.
        Coron Artery Dis. 2005; 16: 321-326
        • Iwakura K.
        • Ito H.
        • Kawano S.
        • Okamura A.
        • Kurotobi T.
        • Date M.
        • Inoue K.
        • Fujii K.
        Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfuse acute myocardial infarction.
        Eur Heart J. 2006; 27: 534-539
        • Hoffmann R.
        • Haager P.
        • Suliman H.
        • Christott P.
        • Radke P.
        • Blindt R.
        • Kelm M.
        Effect of statin therapy before Q-wave myocardial infarction o myocardial perfusion.
        Am J Cardiol. 2008; 101: 139-143
        • Lev E.I.
        • Kornowski R.
        • Vaknin-Assa H.
        • Ben-Dor I.
        • Brosh D.
        • Teplitsky I.
        • Fuchs S.
        • Battler A.
        • Assali A.
        Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
        Am J Cardiol. 2009; 103: 165-169